Amgen look to develop DNA-encoded libraries to increase new drug design innovation
Amgen, after the acquisition of Nuevolution and its world-class DNA-encoded library (DEL) platform, Amgen has a team of expert’s adept at making and screening billions to trillions of compounds to find promising leads. The huge increase in screening power will fuel Amgen’s search for bispecific small molecules that use the body’s cellular machinery to tackle